Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H172

UPID:
ABCG4_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H172; A8K1B5; Q8WWH0; Q8WWH1; Q8WWH2

BACKGROUND:
The ATP-binding cassette sub-family G member 4 (ABCG4) protein functions as an ATP-dependent transporter, crucial for the efflux of sterols such as cholesterol and desmosterol to high-density lipoprotein (HDL). Its role in the efflux mechanism is vital for cellular sterol homeostasis. ABCG4 is also implicated in the brain's amyloid-beta peptide clearance, suggesting a potential role in Alzheimer's disease pathology. The protein's ability to induce apoptosis across various cell types further underscores its biological significance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of ATP-binding cassette sub-family G member 4 offers promising avenues for therapeutic intervention in conditions like hypercholesterolemia and Alzheimer's disease, leveraging its sterol transport and pro-apoptotic capabilities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.